Molecular structure of Roflumilast, CAS Number: 162401-32-3
Roflumilast (CAS 162401-32-3)
See product citations (21)
Alternate Names:
3-(Cyclopropylmethoxy)-N-(3,5-dichloro-4-pyridinyl)-4-(difluoromethoxy)benzamide
Application:
Roflumilast is a selective inhibitor of PDE4 (phosphodiesterase 4)
CAS Number:
162401-32-3
Purity:
≥99%
Molecular Weight:
403.21
Molecular Formula:
C17H14Cl2F2N2O3
For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.
* Refer to Certificate of Analysis for lot specific data.
QUICK LINKS
Ordering Information
Product Citations
Description
Technical Information
Safety Information
SDS & Certificate of Analysis
Roflumilast is a selective PDE4 (phosphodiesterase 4) (IC50 = 0.8 nM) inhibitor. Inhibition of PDE4 prevents the hydrolysis of phosphodiesters, which play a key role in signal transduction. This compound has anti-inflammatory properties and is particularly effective at reducing inflammation in lung tissue.
Roflumilast (CAS 162401-32-3) References
- Roflumilast: APTA 2217, B9302-107, BY 217, BYK 20869. | . 2004. Drugs R D. 5: 176-81. PMID: 15139782
- Roflumilast: a selective phosphodiesterase 4 inhibitor. | Christie, P. 2005. Drugs Today (Barc). 41: 667-75. PMID: 16389409
- Effect of roflumilast on chronic obstructive pulmonary disease: a systematic review and meta-analysis. | Shen, LF., et al. 2018. Ir J Med Sci. 187: 731-738. PMID: 29397527
- Pharmacological mechanism of roflumilast in the treatment of asthma-COPD overlap. | Zhang, X., et al. 2018. Drug Des Devel Ther. 12: 2371-2379. PMID: 30122895
- Roflumilast attenuates cognitive deficits in estrogen insufficient rats. | Goyal, A. and Garabadu, D. 2020. Behav Pharmacol. 31: 671-687. PMID: 32516271
- Roflumilast counteracts DMH-induced preneoplastic colon damage in albino Wistar rats. | Saeedan, AS., et al. 2020. Hum Exp Toxicol. 39: 1545-1555. PMID: 32524861
- Roflumilast, a phosphodiesterase-4 inhibitor, improves hyperoxia-induced lung injury via anti-inflammation. | Cao, HY., et al. 2020. Undersea Hyperb Med. 47: 189-196. PMID: 32574434
- Scope of adjuvant therapy using roflumilast, a PDE-4 inhibitor against COVID-19. | S, SLJ. and V, R. 2021. Pulm Pharmacol Ther. 66: 101978. PMID: 33259924
- Roflumilast prevents ischemic stroke-induced neuronal damage by restricting GSK3β-mediated oxidative stress and IRE1α/TRAF2/JNK pathway. | Xu, B., et al. 2021. Free Radic Biol Med. 163: 281-296. PMID: 33359910
- Inhibitory effect of roflumilast on experimental periodontitis. | Liu, Q., et al. 2022. J Periodontol. 93: 423-434. PMID: 34124777
- Roflumilast Suppresses Adipogenic Differentiation via AMPK Mediated Pathway. | Xu, W., et al. 2021. Front Endocrinol (Lausanne). 12: 662451. PMID: 34163436
- Overexpression of PDE4D in mouse liver is sufficient to trigger NAFLD and hypertension in a CD36-TGF-β1 pathway: therapeutic role of roflumilast. | Tao, X., et al. 2022. Pharmacol Res. 175: 106004. PMID: 34826603
- Rectal roflumilast improves trinitrobenzenesulfonic acid-induced chronic colitis in rats. | Shaikh-Omar, A., et al. 2022. Braz J Med Biol Res. 55: e11877. PMID: 35239781
- The immunomodulatory effects of roflumilast on tachyzoite-bradyzoite transition in a murine model of Toxoplasma gondii. | Elmasry, A., et al. 2022. Int Immunopharmacol. 113: 109348. PMID: 36306559
Inhibitor of:
LA-PF4, LOC642781, PDE, PDE4A, PDE4B, PDE4C, and PDE4D.Activator of:
Blr1, CC10, CIITA, IL-14, neuroserpin, Pap20, PCDHB, Pcdhb17, Pdcd-10, Relaxin 2, resistin, and TREML2.Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
Roflumilast, 5 mg | sc-208313 | 5 mg | $60.00 |